Alzheimer’s research needs international approach

29th May 2015

Alzheimer’s research needs international approachEric Karran

New research initiatives aim to encourage pharma and academia to collaborate on dementia drug discovery, which is a high-risk field historically.Dementia is a global challenge, with 44 million people worldwide... Read more

Tunnah’s musings: building the right relationship between patients and…

28th May 2015

Tunnah’s musings: building the right relationship between patients and pharmaPaul Tunnah

This month, Paul Tunnah is cautiously optimistic that the value of engaging with patients is starting to be recognised across the pharmaceutical industry, but muses on how this should be... Read more

Depression, alcohol and drug problems: the hidden toll of HIV

27th May 2015

Depression, alcohol and drug problems: the hidden toll of HIVDavid Rowlands

David Rowlands examines the results of his most recent poll on standards of psychological care in HIV – an important factor as 96 per cent of respondents agreed that those... Read more

Innovative smaller firms to break into pharma's top 20

26th May 2015

Innovative smaller firms to break into pharma's top 20Andrew McConaghie

After decades of a few major pharma companies dominating the industry, a new generation of small but often highly innovative companies are breaking into the sector's top division, reports Andrew... Read more


Teva pays $1.2bn to settle pay-for-delay deal

29th May 2015

Teva pays $1.2bn to settle pay-for-delay dealStaff reporter

Teva has agreed to pay a whopping $1.2 billion to settle a US lawsuit claiming its subsidiary Cephalon paid to hold up generic competition to its narcolepsy therapy Provigil.In a... Read more

Novartis cuts deal with start-up for oral biologic delivery

28th May 2015

Novartis cuts deal with start-up for oral biologic deliveryStaff reporter

The explosion in biologic R&D means that many new drugs coming onto the market are large molecules delivered by injection, but Novartis wants more to be available for oral dosing.To... Read more

Link cancer drug prices to patient benefits, says Express Scripts

28th May 2015

Link cancer drug prices to patient benefits, says Express ScriptsAndrew McConaghie

One of the most powerful US health insurers is calling on pharma companies to link the prices of their cancer drugs to how well they work in different patients.Dr Steve... Read more

PD-1 inhibitors head latest crop of CHMP opinions

27th May 2015

PD-1 inhibitors head latest crop of CHMP opinionsStaff reporter

Eight new drugs were recommended for approval at the CHMP's latest meeting, with cancer immunotherapies from Merck & Co and Bristol-Myers Squibb (BMS) headlining.Merck's Keytruda (pembrolizumab) was given a green... Read more

Audio & Video

Available on demand: Exclusive debate/we…



The way that physicians want and need to consume information has changed dramatically over recent years and continues to evolve rapidly. Working in... View more

Being Patient-centric is being Family-ce…


Cancer survivor and patient opinion leader Andrew Schorr and his wife Esther Schorr discuss how families should be involved in decision-making around care for patients.... View more

On demand webinar: Staring into the aby…

IMS webinar


Regardless of the colour of the next UK government that emerges as a result of the May election, the £30–50bn NHS budget... View more

Live webinar/debate - Feb 4th - COPD, co…

Join the COPD webinar/debate



COPD is a widespread, costly and largely preventable condition which affects over 300 million people worldwide and is recognised... View more

White Papers

Optimising patient outcomes through phys…

Optimising patient outcomes through physician educationDr James Quekett

Physician education is undergoing a massive change as the volume of advances in therapies and practices increases and the use of digital channels facilitates new forms of scientific exchange. This white... View info

Is pharma brand marketing dead?

Is pharma brand marketing dead?Mark Sales, Fabrice Bourg & Richard Goosey

This comprehensive supplement brings together a series of articles, insights and discussions produced by Kantar Health in order to help stimulate debate and fresh thinking about the future of pharmaceutical... View info

Improved health and wellbeing in COPD

Improved health and wellbeing in COPDAna Maria Arboleda, Clare Maloney & Prof John Weinman

Chronic obstructive pulmonary disease (COPD) is a progressive and debilitating disorder, which, as it progresses, places a significant burden on individuals and those caring for them. This is not only... View info

Computer Gaming: The Future of Decision-…

Computer Gaming: The Future of Decision-Making for Life Sciences?

How can life science brands identify winning strategic decisions when there are so many variables to consider? One route is via 'road-testing' decisions ahead of sign-off under computer game simulated... View info

Further News & Articles

Future of AZ’s psoriasis drug in doubt after Amgen withdrawal

AstraZeneca (AZ) will be forced to make a difficult decision on its psoriasis drug brodalumab after Amgen pulled... Read more


All but one Cancer Drug Fund appeals rejected

Of the four companies that appealed the removal of their drugs from the UK's Cancer Drugs Fund, only Bayer succe... Read more


Is a deal to create 'PfizerKline' in the offing?

The rumour mill has been grinding away furiously in the last few days, focusing mainly on a possible bid for Gla... Read more


10 new cancer drug highlights for ASCO

Researchers are set to reveal the latest good news in cancer research – but questions about price and value won't... Read more


NICE to launch ‘Office for Market Access’

NICE is to establish a new Office for Market Access to help life sciences companies prepare for its cost effecti... Read more


J&J plans to file 10 new blockbusters by 2019

For years, the pharma industry has been saying the era of the blockbuster product is over, but Johnson & Joh... Read more